ScripAstraZeneca and Daiichi Sankyo’s Phase III DESTINY-Breast09 clinical trial testing the antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) plus Roche’s Perjeta (pertuzumab) is the first tri
ScripGilead Sciences is looking to expand the reach of Trodelvy (sacituzumab govitecan-hziy) into the frontline setting of triple-negative breast cancer (TNBC) based on positive topline results in combinat
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure